These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 18927096)
21. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476 [TBL] [Abstract][Full Text] [Related]
22. Utilization of lower gastrointestinal endoscopy and fecal occult blood test in 11 European countries: evidence from the Survey of Health, Aging and Retirement in Europe (SHARE). Stock C; Brenner H Endoscopy; 2010 Jul; 42(7):546-56. PubMed ID: 20432204 [TBL] [Abstract][Full Text] [Related]
23. Prevalence of FOB testing in eastern-Australian general practice patients: what has a national bowel cancer screening program delivered? Paul CL; Carey ML; Russell G; D'Este C; Sanson-Fisher RW; Zwar N Health Promot J Austr; 2015 Apr; 26(1):39-44. PubMed ID: 25818504 [TBL] [Abstract][Full Text] [Related]
24. Factors associated with colon cancer screening: the role of patient factors and physician counseling. Wee CC; McCarthy EP; Phillips RS Prev Med; 2005 Jul; 41(1):23-9. PubMed ID: 15916989 [TBL] [Abstract][Full Text] [Related]
25. Screening for colorectal cancer in Italy: 2005 survey. Zorzi M; Barca A; Falcini F; Grazzini G; Pizzuti R; Ravaioli A; Sassoli de Bianchi P; Senore C; Sigillito A; Vettorazzi M; Visioli C Epidemiol Prev; 2007; 31(2-3 Suppl 2):49-60. PubMed ID: 17824362 [TBL] [Abstract][Full Text] [Related]
26. Patterns of colorectal cancer screening uptake among men and women in the United States. Meissner HI; Breen N; Klabunde CN; Vernon SW Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):389-94. PubMed ID: 16492934 [TBL] [Abstract][Full Text] [Related]
28. Trends in colorectal cancer test use among vulnerable populations in the United States. Klabunde CN; Cronin KA; Breen N; Waldron WR; Ambs AH; Nadel MR Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1611-21. PubMed ID: 21653643 [TBL] [Abstract][Full Text] [Related]
29. Validity of four self-reported colorectal cancer screening modalities in a general population: differences over time and by intervention assignment. Jones RM; Mongin SJ; Lazovich D; Church TR; Yeazel MW Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):777-84. PubMed ID: 18381476 [TBL] [Abstract][Full Text] [Related]
30. Socioeconomic and racial patterns of colorectal cancer screening among Medicare enrollees in 2000 to 2005. Doubeni CA; Laiyemo AO; Reed G; Field TS; Fletcher RH Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2170-5. PubMed ID: 19622721 [TBL] [Abstract][Full Text] [Related]
31. Colorectal cancer screening in asymptomaic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. Cheng TI; Wong JM; Hong CF; Cheng SH; Cheng TJ; Shieh MJ; Lin YM; Tso CY; Huang AT J Formos Med Assoc; 2002 Oct; 101(10):685-90. PubMed ID: 12517041 [TBL] [Abstract][Full Text] [Related]
32. A case-control study to evaluate efficacy of screening for faecal occult blood. Lazovich D; Weiss NS; Stevens NG; White E; McKnight B; Wagner EH J Med Screen; 1995; 2(2):84-9. PubMed ID: 7497161 [TBL] [Abstract][Full Text] [Related]
33. Ontario's ColonCancerCheck: results from canada's first province-wide colorectal cancer screening program. Rabeneck L; Tinmouth JM; Paszat LF; Baxter NN; Marrett LD; Ruco A; Lewis N; Gao J Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):508-15. PubMed ID: 24443406 [TBL] [Abstract][Full Text] [Related]
34. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy? van Dam L; Korfage IJ; Kuipers EJ; Hol L; van Roon AH; Reijerink JC; van Ballegooijen M; van Leerdam ME Eur J Cancer; 2013 Jul; 49(10):2321-30. PubMed ID: 23571149 [TBL] [Abstract][Full Text] [Related]
35. Testing for prostate and colorectal cancer: comparison of self-report and medical record audit. Hall HI; Van Den Eeden SK; Tolsma DD; Rardin K; Thompson T; Hughes Sinclair A; Madlon-Kay DJ; Nadel M Prev Med; 2004 Jul; 39(1):27-35. PubMed ID: 15207983 [TBL] [Abstract][Full Text] [Related]
36. Colorectal cancer test use from the 2005 National Health Interview Survey. Shapiro JA; Seeff LC; Thompson TD; Nadel MR; Klabunde CN; Vernon SW Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1623-30. PubMed ID: 18628413 [TBL] [Abstract][Full Text] [Related]
37. Colorectal cancer screening behavior in women attending screening mammography: longitudinal trends and predictors. Carlos RC; Fendrick AM; Abrahamse PH; Dong Q; Patterson SK; Bernstein SJ Womens Health Issues; 2005; 15(6):249-57. PubMed ID: 16325138 [TBL] [Abstract][Full Text] [Related]
38. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial. Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385 [TBL] [Abstract][Full Text] [Related]
39. Flexible sigmoidoscopy following a positive faecal occult blood test within a bowel screening programme may reduce the detection of neoplasia. Mansouri D; McMillan DC; Roxburgh CS; Moug SJ; Crighton EM; Horgan PG Colorectal Dis; 2013 Nov; 15(11):1375-81. PubMed ID: 23927751 [TBL] [Abstract][Full Text] [Related]
40. A population-based estimate of the extent of colorectal cancer screening in Ontario. Rabeneck L; Paszat LF Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]